Hims & Hers Health, Inc.
US ˙ NYSE

Introduction

This page provides a comprehensive analysis of the known insider trading history of Kare Schultz. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Kare Schultz has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:HIMS / Hims & Hers Health, Inc. Director 9,118
US:TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) President and CEO, Director 1,542,471
US:IFF / International Flavors & Fragrances Inc. Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Kare Schultz. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases HIMS / Hims & Hers Health, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in HIMS / Hims & Hers Health, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HIMS / Hims & Hers Health, Inc. Insider Trades
Insider Sales HIMS / Hims & Hers Health, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in HIMS / Hims & Hers Health, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HIMS / Hims & Hers Health, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Kare Schultz as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-16 2025-06-12 4 HIMS Hims & Hers Health, Inc.
Class A Common Stock
M - Exercise 9,118 9,118
2022-11-02 2022-11-01 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 116,389 1,542,471 8.16
2022-05-06 2022-05-05 4 IFF INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units
M - Exercise -1,089 0 -100.00
2022-05-06 2022-05-05 4 IFF INTERNATIONAL FLAVORS & FRAGRANCES INC
Common Stock
M - Exercise 1,089 1,344 427.06
2022-05-06 2022-05-04 4 IFF INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units
A - Award 1,245 1,245
2022-03-08 2022-03-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -71,292 213,879 -25.00
2022-03-08 2022-03-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 71,292 1,426,082 5.26
2022-03-08 2022-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
A - Award 402,144 402,144
2022-03-08 2022-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -162,593 0 -100.00
2022-03-08 2022-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -59,701 59,702 -50.00
2022-03-08 2022-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 162,593 1,354,790 13.64
2022-03-08 2022-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 59,701 1,192,197 5.27
2022-03-02 2022-02-28 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -65,047 130,096 -33.33
2022-03-02 2022-02-28 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 65,047 1,132,496 6.09
2022-02-10 2022-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -26,867 0 -100.00
2022-02-10 2022-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 26,867 1,067,449 2.58
2022-02-10 2022-02-08 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
A - Award 162,593 162,593
2021-11-03 2021-11-01 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -180,000 116,389 -60.73
2021-11-03 2021-11-01 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 180,000 1,040,582 20.92
2021-05-07 2021-05-06 4 IFF INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units
M - Exercise -255 0 -100.00
2021-05-07 2021-05-06 4 IFF INTERNATIONAL FLAVORS & FRAGRANCES INC
Common Stock
M - Exercise 255 255
2021-05-07 2021-05-05 4 IFF INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units
A - Award 1,089 1,089
2021-03-08 2021-03-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
A - Award 285,171 285,171
2021-03-08 2021-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -59,701 119,403 -33.33
2021-03-08 2021-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 59,701 860,582 7.45
2021-03-03 2021-03-01 4 IFF INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units
A - Award 255 255
2021-03-02 2021-02-28 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -65,047 195,143 -25.00
2021-03-02 2021-02-28 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 65,047 800,881 8.84
2021-02-11 2021-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -26,867 26,867 -50.00
2021-02-11 2021-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
A - Award 226,173 735,834 44.38
2021-02-11 2021-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 26,867 509,661 5.56
2020-11-03 2020-11-03 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -212,314 0 -100.00
2020-11-03 2020-11-03 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 212,314 482,794 78.50
2020-11-03 2020-11-01 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -180,000 296,389 -37.78
2020-11-03 2020-11-01 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 180,000 270,480 198.94
2020-03-03 2020-02-28 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
A - Award 260,190 260,190
2020-02-13 2020-02-11 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
A - Award 212,314 212,314
2020-02-11 2020-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -26,867 53,734 -33.33
2020-02-11 2020-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 26,867 90,480 42.24
2019-11-05 2019-11-03 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -63,613 476,389 -11.78
2019-11-05 2019-11-03 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 63,613 63,613
2019-03-06 2019-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
A - Award 179,104 179,104
2018-02-12 2018-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
A - Award 80,601 80,601
2018-02-12 2018-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Stock Options (right to buy)
A - Award 205,482 205,482
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)